ECOG E2112 A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Men and Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer

Objective

This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating postmenopausal patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph nodes or another place in the body. Estrogen can cause the growth of breast cancer cells. Endocrine therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether exemestane is more effective with or without entinostat in treating breast cancer.

https://www.clinicaltrials.gov/ct2/show/NCT02115282

Contact Phone: 218-786-3308 | 1-844-681-7944

Email: cancertrials@essentiahealth.org

Locations: Essentia Health Cancer Centers

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 06/04/2018

Research Study Categories

  • Adult Studies

Specialty

  • Cancer
  • Breast Cancer